Latest news with #HEL
Yahoo
14-05-2025
- Business
- Yahoo
Faron Pharmaceuticals Ltd: Grant of Options
TURKU, FINLAND / / May 14, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN): Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, todayannounces that the Company's board has confirmed the grant of a total of 876,000options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019 (including its UK and US sub plans). The Options have been allocated under the Share Option Plan 2019 and are exercisable between April 4, 2026 and April 4, 2031, vesting 25% per annum over four years. The exercise price for Options allocated under the Share Option plan is €2.20 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 90 days preceding the allocation date of 4 April 2025. The exercise price for Options allocated under the US sub plan is €2.31 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 30 days preceding the allocation date of 4 April 2025. The terms of the Share Option Plan 2019 are available on the Company's website at The granted 876,000 Options entitle the option holders to subscribe for a total of 876,000new ordinary shares in the Company, if exercised in full, and represent 0.78 %of the fully diluted ordinary share capital of the Company. Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities ("PDMRs") and Company personnel: Director Options granted Colin Bond 30,000 Marie-Louise Fjällskog 30,000 Juho Jalkanen 200,000 Markku Jalkanen 30,000 John Poulos 30,000 Tuomo Tuomo Pätsi 100,000 Christine Roth 30,000 Total directors 450,000 Other PDMR Maija Hollmén 6,000 Vesa Karvonen 30,000 Yrjö Wichmann 60,000 Kaisa Kyttä 11,000 Petri Bono 30,000 Total other PDMRs 137,000 Total Company personnel 876,000 For more information, please contact: IR Partners, Finland(Media)Riina TuominenKare Laukkanen +358 44 313 50 553 9535 / +44 7 469 766 FINN Partners, US(Media) Alyssa Paldo +1 847 791-8085 Cairn Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner +44 (0) 207 213 0880 Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka Järvelä +358 (0)40 555 4727+358 (0)50 553 8990 About BEXMABThe BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes. About Bexmarilimab Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care. About Faron Pharmaceuticals Ltd. Faron (AIM:FARN)(First North:FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated a. Name a) Colin Bondb) Marie-Louise Fjällskogc) Juho Jalkanend) Markku Jalkanene) John Poulosf) Tuomo Pätsig) Christine Rothh) Maija Hollméni) Vesa Karvonenj) Yrjö Wichmannk) Kaisa Kyttäl) Petri Bono 2 Reason for notificationa. Position/Status Person discharging managerial responsibilities/person closely associated b. Initial notification/Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Faron Pharmaceuticals Oy b. LEI 7437009H31TO1DC0EB42 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a. Description of the financial instrument, type of instrumentIdentification Code Options over new ordinary sharesISIN: FI4000153309 b. Nature of the transaction Grant of options made under the Faron Share Option Plan 2019 - under the UK and US sub plans the options are exercisable at €2.20 per ordinary share, and at €2.31 per ordinary share respectively. c. Price(s) and volume(s)Price(s) Volume(s) a) €2.20b) €2.31c) €2.20d) €2.20e) €2.31f) €2.20g) €2.31h) €2.20i) €2.20j) €2.20k) €2.20l) €2.20 a) 30,000b) 30,000c) 200,000d) 30,000e) 30,000f) 100,000g) 30,000h) 6,000i) 30,000j) 60,000k) 11,000l) 30,000 d. Aggregated information- Aggregated Volume- Price Nil e. Date of the transaction 14 May 2025 f. Place of the transaction Turku SOURCE: Faron Pharmaceuticals View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
BBC News
01-04-2025
- Business
- BBC News
Firm linked to Crooked House goes into liquidation
A firm linked to the ex-owner of the Crooked House pub, which was gutted by fire before being demolished illegally, has gone into liquidation with debts of £ Environmental Ltd (HEL), which owns the 15-hectare Oak Farm Quarry and Landfill site adjacent to the pub, which was reduced to a pile of bricks nearly two years ago, has been wound up voluntarily, Companies House October, the Environment Agency (EA) obtained an injunction against the firm over a risk of pollution and to human health on the land, near Adam Taylor was a director of HEL and a previous director of the firm that bought the pub from Marstons in July 2023. The Crooked House - whose demolition sparked widespread anger and a campaign to get it rebuilt - was bought by ATE Farms Limited, based in Bedworth, Taylor's wife Carly was also a director, before she stepped down from the firm last December. Information at Companies House stated that members of HEL met and agreed to it being wound up on 13 March, when a liquidator was also a notice of statement of affairs, the company's estimated total deficiency was listed at £1.2m. Potential criminal proceedings An investigation by the BBC's File on 4 in 2023 revealed the company was taken to court over a failure to comply with orders from the EA.A notice was issued to HEL in 2021, when Mr Taylor was described by Companies House as a person with "significant control" of the company. He is no longer a director. The Crooked House was destroyed in a suspected arson attack in August people arrested last year were released from bail last July, but remain under investigation, Staffordshire Police has Staffordshire Council has served an enforcement order on the owners ordering them to rebuild the pub within three years.A planning enforcement public inquiry, requested by the pub's owners, has been postponed until after any potential criminal proceedings are concluded. Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram.
Al Bawaba
05-02-2025
- Science
- Al Bawaba
Photo of US Navy firing off laser weapon causes a stir
Published February 5th, 2025 - 11:13 GMT ALBAWABA - A picture showing the newly developed US Navy with a laser weapon has caused a buzz on social media with people crazy to discover more about the "drone destroyer". The photo of the US Navy laser weapon, identified as HELIOS, was posted first via the US Center for Countermeasures' annual report and quickly became widely circulating online. HELIOS was developed for the US by Lockheed Martin and it uses a 60 kW high-energy laser that can destroy objects in a matter of seconds. In the footage, the warfighting laser technology was seen coming out of the USS Preble destroyer in the middle of the ocean. The US Navy released a clip of the USS Preble firing a HELIOS laser weapon. The High Energy Laser with Integrated Optical-Dazzler and Surveillance will be used primarily to counter — Massimo (@Rainmaker1973) February 3, 2025 The picture was shared "to verify and validate the functionality, performance, and capability of the HEL with Integrated Optical Dazzler and Surveillance system against an unmanned aerial vehicle target," the report revealed. The United States in fact was not the only country to test a laser weapon, last year, the UK tested a locally developed high-powered laser weapon, known as DragonFire, and attacked an aerial object. Many comments emerged on social media where a few people said the laser weapon looked like coming out of a "Star Wars movie". A person said: "Who are they preparing to fight Godzilla?" Another wrote: "i'd be interested in knowing how it can handle 100 drones all at once." © 2000 - 2025 Al Bawaba (
